| Eylea (aflibercept intravitreal) / Bayer, Regeneron |
ACTRN12617001487303: Intravitreal Aflibercept for the Treatment of Treatment Resistant Macular Oedema secondary to Retinal Vein Occlusions |
|
|
| Recruiting | 4 | 50 | | | A/Prof Andrew Chang, Bayer Australia Limited | macular oedema secondary to retinal vein occlusion | | | | |
ACTRN12612000666820: Intravitreal Aflibercept for the treatment of previously treated exudative age-related macular degeneration |
|
|
| Recruiting | 4 | 70 | | | Andrew Chang, Andrew Chang | Exudative age-related macular degeneration | | | | |
ACTRN12614001307695: Intravitreal Aflibercept for the Treatment of Treatment Resistant Diabetic Macular Oedema |
|
|
| Recruiting | 4 | 50 | | | Andrew Chang, Andrew Chang, primary investigator | Diabetic Macular Oedema | | | | |
ACTRN12619000963123: Aflibercept for Diabetic Macular Oedema: Outcomes Using a Treat and Extend Protocol |
|
|
| Recruiting | 4 | 50 | | | The Royal Adelaide Hospital, Bayer Australia Limited | Diabetic Macular Oedema | | | | |
2013-001208-12: Switching to aflibercept in patients with wet AMD not responding to anti-VEGF treatment. |
|
|
| Ongoing | 4 | 20 | Europe | Eylea, Solution for injection, Eylea | Radboud University Nijmegen Medical Centre, Bayer HealthCare | Neovascular Age-related macular degeneration, wet age-related macular degeneration, Diseases [C] - Eye Diseases [C11] | | | | |
2014-003229-17: To compare two different treatment intervals when treating patients with wet macular disease with Eyelea and to examine the effect of the treatment on the sight cells. Att jämföra två olika behandlings intervall med eylea för våt AMD och att medels ERG (elektrofysiologi) se effekten på syncellernas funktion |
|
|
| Ongoing | 4 | 40 | Europe | aflibercept, SO1LAO5, Intravitreal implant in applicator, Aflibercept | Inst of OPhthalmology, Lund University, Inst of OPhthalmology, Lund University | To evaluate if Aflibercept given every eighth week from start after an initial loading dose in age-related macular degeneration (AMD), is as effective as dosing as "Treat and extend" where treating intervalls are prolonged after stability in visual acuity is achieved. Followed for 18 months. The secondary objective is to evaluate the safety of Aflibercept assessed with ERG, and a quality of life questioner will be put to all patients at start and at follow-up after 18 months. Primär målsättning: Att undersöka om Aflibercept doserat varannan månad efter tre initial månatliga injektioner är lika effektivt som att dosera enligt treat-and-extend regimen där intervallen förlängs efter att maximal synskärpa uppnåtts hos patienter med våt AMD under 18 månader. Sekundär målsättning: Undersöka retinala funktionen efter injektion av Aflibercept mätt med ERG, samt ett livskvalitetsformulär kommer att distribueras till patienterna före/efter behandling., To evaluate if Eylea injections into the eye for wet macular degenerations, can be extended and given with longer intervals. Att undersöka om intervallen mellan Eylea sprutat i ögat vid våt maculasjukdom kan förlängas, Diseases [C] - Eye Diseases [C11] | | | | |
2014-002168-34: Aflibercept Efficacy in Patients Suffering Age-Related Damage of the Yellow Spot of the Light-sensitive Tissue Layer in the Eye Účinnosti Afliberceptu u pacientů trpících věkem způsobeným poškozením žluté skvrny sítnice oka. |
|
|
| Ongoing | 4 | 45 | Europe | Injection, Eylea | Doc. MUDr. Petr Kolář, PhD, Oční klinika FN Brno, Bayer s.r.o. | Retinal angiomatous proliferation secondary to wet age related macular degeneration. Zmnožení cév uvnitř sítnice způsobené „vlhkou“ formou věkem podmíněné makulární degenerace (VPMD)., Wet form of age-related damage of the macula with abnormal proliferation of retinal blood vessels (associated with blood leakage as well as epithelial detachments). Při vlhké formě VPMD se v centrální oblasti sítnice (zvané makula, žlutá skvrna) abnormálně vytvářejí krevní cévy, které jsou slabé a prosakují, což způsobuje jizvení poškozující sítnici., Diseases [C] - Eye Diseases [C11] | | | | |
2015-001394-41: Aflibercept treatment in age-related macular degeneration Aflibersepti kostean ikärappeuman lasiaisinjektiohoidossa |
|
|
| Ongoing | 4 | 50 | Europe | Injection, Eylea | Raimo Tuuminen, University of Helsinki | Wet age-related macular degeneration Silmänpohjan kostea ikärappeuma, Wet age-related macular degeneration Silmänpohjan kostea ikärappeuma, Diseases [C] - Eye Diseases [C11] | | | | |
2015-000959-24: Investigation of Eylea for patients with diabetic macular edema in an outpatient Setting. |
|
|
| Ongoing | 4 | 50 | Europe | Eylea, Injection, Eylea | Abteilung für Augenheilkunde, AKH Linz, Bayer | Diabetic Retinopathy and diabetic macular edema are leading causes for visual loss and blindness in young adults around the world., Diabetic Macular Edema, Diseases [C] - Eye Diseases [C11] | | | | |
2014-000300-10: Study, to evaluate the effectiveness of aflibercept in patients with RAP (retinal angiomatous proliferation) lesions. Estudio para evaluar la eficacia de aflibercept en pacientes con lesiones RAP (proliferación angiomatosa de la retina) |
|
|
| Ongoing | 4 | 50 | Europe | Eylea, Eylea, Eylea, Eylea | Fundació Instituto de Investigación Biomédica de Bellvitge (Fundació IDIBELL), Bayer | Retinal angiomatous proliferation lesions (RAP) Lesiones de proliferación angiomatosa de la retina (RAP) | | | | |
2014-000975-21: Study to evaluate the effectiveness of aflibercept in patients with macular edema secondary to central retinal vein occlusion. Estudio para evaluar la eficacia de aflibercept en pacientes con edema macular secundario a oclusión de la vena central de la retina. |
|
|
| Ongoing | 4 | 50 | Europe | Eylea, Eylea, Eylea, Eylea | Fundación Retinaplus +, Bayer | Macular edema secondary to central retinal vein occlusion. Edema macular secundario a oclusión de la vena central de la retina. | | | | |
| Completed | 4 | 51 | NA | EYLEA 2 MG in 0.05 ML Injection | University of Athens | Retinal Vein Occlusion, Vascular Occlusive Disease | 12/20 | 03/24 | | |
2016-004608-78: The Effect of Intravitreal Aflibercept on Ocular Perfusion – a Pilot Study |
|
|
| Ongoing | 4 | 20 | Europe | Aflibercept, EMA/CHMP/299413/2012, Solution for injection, Eylea | Kepler University Hospital, Institute of Ophthalmology, Kepler-University Hopsital | Exudative AMD, Exudativ age related macular degeneration, Diseases [C] - Eye Diseases [C11] | | | | |
2016-001660-10: Antibody treatment in retinal vein occulsion and the influence on oxygen and blood supply |
|
|
| Ongoing | 4 | 30 | Europe | aflibercept, SUB26987, Solution and suspension for suspension for injection in pre-filled syringe, Eylea 40mg/ml | Universitätsklinik für Augenheilkunde und Optometrie, Univ Klinik für Augenheilkunde und Optometrie | retinal vein occlusion, retinal vein occlusion, Diseases [C] - Eye Diseases [C11] | | | | |
2019-003133-42: Treatment of neovascular AMD: Artificial intelligence in real-world setting |
|
|
| Not yet recruiting | 4 | 290 | Europe | Lucentis, Eylea, Beovu, EMEA/H/C/000715, EMEA/H/C/002392, EMEA/H/C/004913, Solution for injection, Lucentis, Eylea, Beovu | Medical University of Vienna, Department of Ophthalmology and Optometry, MUW, Department of Ophthalmology and Optometry | Nevoascular age related macular degneration (nAMD), wet macular degeneration, Diseases [C] - Eye Diseases [C11] | | | | |
NCT06330220: Visual Function Change in Wet Age-related Macular Degeneration Patients With Better Baseline Visual Acuity |
|
|
| Completed | 4 | 12 | RoW | Aflibercept Injection [Eylea], Eylea injection | Seoul National University Hospital | Age-Related Macular Degeneration | 02/22 | 02/22 | | |
2020-005449-18: Spontaneous retinal artery pulses as a prognostic determinant of central retinal vein occlusions in patients with and without intravitreal aflibercept injections Pulsations artérielles rétiniennes spontanées (PARS) en tant que déterminant pronostique des occlusions de la veine centrale de la rétine (OVCR) chez les patients traités ou non par injections intravitréennes d’aflibercept |
|
|
| Not yet recruiting | 4 | 60 | Europe | Solution for injection, Eylea 40 mg/mL, solution injectable en seringue préremplie | Hôpital Fondation A. de Rothschild / Service de recherche clinique, Bayer Healthcare | Central retinal vein occlusions Occlusions de la veine centrale de la rétine (OVCR), Central retinal vein occlusions Occlusions de la veine centrale de la rétine (OVCR), Diseases [C] - Eye Diseases [C11] | | | | |
2020-003515-10: To Study Aqueous Humor Composition and Retinal Imaging Features in Response to Anti-VEGF in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema STUDIE BIOMARKERŮ INHIBITORŮ VEGF ZKOUMAJÍCÍ VZTAH MEZI SLOŽENÍM KOMOROVÉ VODY A MULTIMODÁLNÍMI SNÍMKY SÍTNICE PŘI VLHKÉ FORMĚ VĚKEM PODMÍNĚNÉ MAKULÁRNÍ DEGENERACE A DIABETICKÉM MAKULÁRNÍM EDÉMU |
|
|
| Ongoing | 4 | 200 | RoW | Aflibercept, Solution for injection in pre-filled syringe, Eylea® | F. Hoffmann-La Roche Ltd, F. Hoffmann-La Roche Ltd | Treatment Naïve Neovascular Age-Related Macular Degeneration (nAMD) and Treatment Naïve diabetic macular edema (DME), nAMD is an eye disease particularly affects the center of sharp vision (e.g affects reading or driving). DME is a complication of diabetes and causes problem in vision (e.g blurred or wavy vision)., Diseases [C] - Eye Diseases [C11] | | | | |
2021-001058-73: Comparison of brolucizumab and aflibercept in retinal angiomatous proliferation form of wet age related macular degeneration - prospective randomised study Srovnání brolucizumabu a afliberceptu v terapii retinální angiomatózní proliferace - varianty vlhké formy věkem podmíněné makulární degenerace |
|
|
| Not yet recruiting | 4 | 60 | RoW | Solution for injection in pre-filled syringe, Beovu, Eylea | Fakultní nemocnice Královské Vinohrady, Fakultní nemocnice Královské Vinohrady, Fakultní nemocnice Hradec Králové, Fakultní nemocnice Ostrava | Retinal angiomatous proliferation form of neovascular age related macular degeneration (AMD). Renitální angiomatózní proliferace - varianta vlhké formy věkem podmínění makulární degenerace (VPMD)., Retinal angiomatous proliferation is a form of neovascular AMD - an eye disease that worsens the vision due to abnormal blood vessels that leak fluid or blood into retina. Retinální angiomatózní proliferace je variantou neovaskulární formy VPMD - onemocnění oka, které zhoršuje vidění vlivem abnormálních krevních cév, které prosakují tekutinu nebo krev do sítnice., Diseases [C] - Eye Diseases [C11] | | | | |
NCT03999125: Anti-VEGF Therapy Versus Dexamethasone Implant for DME |
|
|
| Not yet recruiting | 4 | 150 | Europe | Aflibercept,, Ranibizumab, Dexamethasone Implant, Laser, Ranibizumab Injection, Dexamethasone Implant, Aflibercept, Laser, Ozurdex Drug Implant Product | Sudhalkar Eye Hospital | Clinically Significant Macular Edema Due to Diabetes Mellitus | 06/21 | 06/23 | | |
ChiCTR2300067476: Study on the Effect of Different anti-VEGF drugs on Fibrovascular Membrane of Proliferative Diabetic Retinopathy |
|
|
| Completed | 4 | 24 | | Ranibizumab ;Conbercept ;Aflibercept | Tianjin Medical University Eye Hospital; Tianjin Medical University Eye Hospital, Self-financing | diabetic retinopathy | | | | |
NCT03709745: Eylea and Lucentis for Macular Edema in Branch Retinal Vein Occlusion |
|
|
| Recruiting | 4 | 110 | Europe | Aflibercept Injection [Eylea], Eylea, Ranibizumab Injection [Lucentis], Lucentis | St. Erik Eye Hospital | Branch Retinal Vein Occlusion With Macular Edema | 11/21 | 08/22 | | |
ChiCTR2000037469: The efficacy of arbazepril and ranibizumab in the treatment of retinopathy of prematurity - A prospective randomized controlled trial |
|
|
| Not yet recruiting | 4 | 80 | | intravitreal injection of aflibercept ;intravitreal injection of ranibizumab | Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine; Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai Hospital Development Center | retinopathy of prematurity | | | | |
NCT05282420: Ranibizumab Versus Aflibercept for CRVO in Young Patients. |
|
|
| Recruiting | 4 | 40 | RoW | intravitreal injection of Ranibizumab, intravitreal injection of Aflipercept, Ranibizumab, Aflibercept | Qena Faculty of medicine, South Valley University | Non-Ischemic Central Retinal Vein Occlusion With Macular Edema | 04/22 | 05/22 | | |
STAMP, NCT03832179: Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification |
|
|
| Recruiting | 4 | 32 | US | Bevacizumab, Avastin, Ranibizumab, Lucentis, Aflibercept, Eylea, Ozurdex, Dexamethasone implant | Bay Area Retina Associates, Allergan | Diabetic Macular Edema, Cataract | 07/22 | 10/22 | | |
NCT02681783: PRedictive Factors and Changes From Treatment in iPCV Versus CSR Versus nAMD With afLibercept |
|
|
| Recruiting | 4 | 90 | Canada | aflibercept, Eylea | Sunnybrook Health Sciences Centre | Central Serous Chorioretinopathy, Age Related Macular Degeneration, Idiopathic Poplypoidal Choroidal Vasculopathy | 12/22 | 12/22 | | |
ChiCTR2200057703: A multicenter, single arm clinical trial of intravitreal injection of Aflibercept in patients with neovascular age-related macular degeneration complicated with type I choroidal neovascularization with low response to ranibizumab or Conbercept |
|
|
| Not yet recruiting | 4 | 30 | | Injection of Aflibercept | West China Hospital of Sichuan University; West China Hospital of Sichuan University, Bayer Medical Healthcare Co., LTD. | Neovascular age-related macular degeneration (nAMD) | | | | |
2022-000690-73: A study to learn how well Aflibercept injected into the eye works and how safe it is when given in customized treatment intervals in patients with an eye disease called neovascular age-related macular degeneration after start of treatment |
|
|
| Not yet recruiting | 4 | 108 | Europe | Aflibercept, BAY 86-5321, Solution for injection, Eylea 40mg/ml solution for injection | Bayer AG, Bayer AG | Neovascular (wet) age-related macular degeneration, An eye disorder caused by abnormal blood vessels that leak fluid into the central part of the retina at the back of the eye leading to blurring or a blind spot in the central (straight ahead) vision, Diseases [C] - Eye Diseases [C11] | | | | |
NCT05662410: Choroidal Morphology Changes After Aflibercept Therapy in Pachychoroid Neovasculopathy |
|
|
| Not yet recruiting | 4 | 30 | NA | Three monthly injections of intravitreal aflibercept | Kim's Eye Hospital, Nune Eye Hospital, Seoul, Korea, HanGil Eye Hospital | Pachychoroid Neovasculopathy | 06/23 | 12/23 | | |
XPAND, NCT05473715: A Study to Learn How Well Aflibercept Injected Into the Eye Works and How Safe it is When Given in Customized Treatment Intervals in Patients With an Eye Disease Called Neovascular Age-related Macular Degeneration After Start of Treatment |
|
|
| Terminated | 4 | 3 | Europe, Canada | Aflibercept(BAY86-5321, Eylea) | Bayer, Regeneron Pharmaceuticals | Neovascular (Wet) Age-related Macular Degeneration | 07/23 | 07/23 | | |
NCT05710471: Treatment of Recalcitrant Neovascular AMD Using Brolocizumab With Immediate T&E |
|
|
| Completed | 4 | 30 | RoW | Brolucizumab, Beovu, Aflibercept, Eylea | The University of Hong Kong | Age-Related Macular Degeneration | 07/23 | 08/23 | | |
PRECISION, NCT04411693: Comparative Study of Dexamethasone Implant to Intravitreal Aflibercept in Subjects With Diabetic Macular Edema |
|
|
| Completed | 4 | 23 | US | Dexamethasone implant, Ozurdex, Aflibercept, Eylea | The Cleveland Clinic, Allergan | Diabetic Macular Edema | 01/24 | 01/24 | | |
NCT04707625: Vascular Endothelial Growth Factor (VEGF) Levels in Retinal Vein Occlusion (RVO) During Anti-VEGF Treatment |
|
|
| Terminated | 4 | 17 | US | Aflibercept Ophthalmic, Eylea | Wake Forest University Health Sciences | Retinal Vein Occlusion | 12/23 | 12/23 | | |
NCT05610488: Intravitreal Faricimab in Diabetic Macular Edema With Limited Response to Aflibercept |
|
|
| Not yet recruiting | 4 | 30 | NA | FARICIMAB 6 Mg in 0.05 mL INTRAVITREAL INJECTION, SOLUTION [VABYSMO], Vabysmo | Vista Klinik | Diabetic Macular Edema | 12/23 | 12/23 | | |
NCT04655482: Treat-and-extend Using Aflibercept for Type 3 Neovascularization |
|
|
| Recruiting | 4 | 30 | RoW | Aflibercept Injection, Intravitreal injection of aflibercept (Eylea, Bayer co.) | Kim's Eye Hospital, Bayer | Retinal Angiomatous Proliferation | 12/23 | 08/24 | | |
| Recruiting | 4 | 168 | Canada | Intravitreal aflibercept, Eylea | Unity Health Toronto | Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Macular Edema | 02/24 | 02/24 | | |
ChiCTR2300069732: Study on the pathological mechanism of macular edema caused by retinal vein occlusion and related factors affecting treatment prognosis by MLC combined with aqueous humor cytokine detection |
|
|
| Not yet recruiting | 4 | 60 | | Intravitreal injection of Aflibercept ;Intravitreal injection of Ozurdex | Qingdao Eye Hospital of Shandong First Medical University ; Qingdao Eye Hospital of Shandong First Medical University, Qingdao Eye Hospital introduced doctoral research funds | Retinal vein occlusion | | | | |
VISION-AF, NCT05511038: A Study to Learn How Safe the Study Drug Intravitreal (Given by an Injection Into the Eye) Aflibercept is in Participants in India With Diabetic Macular Edema |
|
|
| Completed | 4 | 100 | RoW | Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | Bayer | Diabetic Macular Edema | 04/24 | 04/24 | | |
ChiCTR2100046527: The clinical research of Yiqi Yangyin Huoxue Lishui combined with aflibercept on diabetic macular edema |
|
|
| Recruiting | 4 | 100 | | Treatment with aflibercept ;Yiqi Yangyin Huoxue Lishui combined with aflibercept | Chongqing Aier Eye Hospital; Chongqing Aier Eye Hospital Co. Ltd, Chongqing Science and Health Union | diabetic macular edema | | | | |
FAN, NCT05941715: Faricimab for High-frequent Aflibercept Treated Neovascular Age-related Macular Degeneration |
|
|
| Active, not recruiting | 4 | 70 | Europe | Aflibercept 40 MG/ML, Eylea®, Faricimab 120 MG/ML, Vabysmo® | Medical University of Graz | Neovascular Age-related Macular Degeneration | 10/24 | 02/25 | | |
VOYAGE, NCT04708145: Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Retinopathy for Subjects Who Completed the 2-Year PANORAMA Trial |
|
|
| Active, not recruiting | 4 | 150 | US | Aflibercept Injection, Eylea | Greater Houston Retina Research, Regeneron Pharmaceuticals, Clinical Trials Resource Group, LLC | Diabetic Retinopathy | 09/24 | 09/24 | | |
NCT05990829: Compare the Efficacy of VItrectomy Combined With DExamethasone Implant Versus With Aflibercept in DME Patients Diagnosed by Intraoperative OCT (the VIDEO Study): Study Protocol for a Randomized Controlled Trial |
|
|
| Recruiting | 4 | 64 | RoW | Ozurdex, Aflibercept | Tianjin Medical University Eye Hospital, Abbvie Pharmaceutical Trading (Shanghai) Co., Ltd. | Diabetic Macular Edema, Pars Plana Vitrectomy, Dexamethasone Intravitreal Implant, Intraoperative Optical Coherence Tomography | 10/24 | 04/25 | | |
NCT02321267: Cohort Study of the Clinical Course of Macular Diseases in Kagawa |
|
|
| Recruiting | 4 | 1000 | Japan | ranibizumab, aflibercept, pegaptanib, verteporphin, Lucentis, Eylea, Macugen, Vizudyne | Kagawa University | Macular Disease | 12/24 | 12/24 | | |
NCT04469595: A Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME) |
|
|
| Active, not recruiting | 4 | 300 | US | Iluvien 0.19 MG Drug Implant, ILUVIEN, Aflibercept, Eylea | Alimera Sciences | Diabetic Macular Edema | 12/24 | 12/24 | | |
ACTRN12613001020774: To investigate the role of Intravitreal Aflibercept (Eylea) in the treatment of patients whose wet Age related Macular degeneration is not adequately controlled with conventional anti VEGF (intravitreal Avastin or Lucentis) treatment. |
|
|
| Not yet recruiting | 3/4 | 50 | | | Greenlane Clinical Centre Auckland District Health Board, Auckland District Health Board | Exudative (Wet) Age related Macular Degeneration | | | | |
ACTRN12614000497606: The RAAMP study. Ranibizumab versus aflibercept for age-related macular degeneration, using multifocal objective pupil perimetry. |
|
|
| Recruiting | 3 | 60 | | | Australian National University (ANU), NHMRC | wet age related macular degeneration (AMD) | | | | |
2014-000272-26: A Multicentre Phase III Double-masked Randomised Controlled Non-Inferiority Trial comparing the clinical and cost effectiveness of intravitreal therapy with ranibizumab (Lucentis) vs aflibercept (Eylea) vs bevacizumab (Avastin) for Macular Oedema (MO) due to Central Retinal Vein Occlusion (CRVO). |
|
|
| Ongoing | 3 | 459 | Europe | Aflibercept, Bevacizumab, Lucentis, EMA/CHMP/299413/2012, EU/1/04/300/001, Solution for injection, Concentrate for solution for injection, Eylea, Avastin, Lucentis | Moorfields Eye Hospital NHS Foundation Trust, NIHR HTA CET | Macular Oedema due to Central Retinal Vein Occlusion (CRVO)., Swelling of the centre of the retina, the light detecting layer at the back of the eye, due to blockage of a blood vessel that usually drains blood out of this layer., Diseases [C] - Eye Diseases [C11] | | | | |
2019-001031-31: Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Patients with Visual Impairment due to Diabetic Macular Edema |
|
|
| Not yet recruiting | 3 | 356 | Europe | RTH258, RTH258 formerly ESBA1008, Solution for injection, Eylea | Novartis Pharma GmbH, Novartis Pharma GmbH | diabetic macular edema, diabetic macular edema, Diseases [C] - Eye Diseases [C11] | | | | |
NCT04955171: BEOVU Versus Eylea in the Treatment of Diabetic Macular Edema |
|
|
| Recruiting | 3 | 60 | RoW | BEOVU intravitreal injection, Brolucizumab-Dbll intravitreal injection | Benha University | Macular Edema | 03/22 | 04/22 | | |
2021-004530-11: Randomized, Phase 3, Double Masked, Parallel Group, Multicenter Study to Compare the Efficacy and Safety of ALT L9 Versus Eylea® |
|
|
| Ongoing | 3 | 444 | Europe, RoW | Aflibercept biosimilar, Eylea®, ALT-L9, Solution for injection, Solution for infusion in pre-filled syringe, Eylea® | Altos Biologics Inc., Altos Biologics Inc. | Neovascular Age Related Macular Degeneration, Eye disease that can blur central vision, Diseases [C] - Eye Diseases [C11] | | | | |
2020-005875-10: Study to collect long-term data on patients treated in the VGFTe-ROP-1920 study that compared intravitreal aflibercept to laser photocoagulation |
|
|
| Not yet recruiting | 3 | 112 | Europe | Eylea, Solution for injection, Eylea 40 mg/ml | Regeneron Pharmaceuticals. Inc., Regeneron Pharmaceuticals, Inc. | Retinopathy of prematurity (ROP), Retinopathy of prematurity (ROP), Diseases [C] - Eye Diseases [C11] | | | | |
ChiCTR2100053500: Canceled by the investigator A Prospective, Randomized, Double-Masked, Active Comparator-Controlled, Multi-Center, Two-Arm, Phase III Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Visual Impairment Secondary to Treatment-Naive Diabetic M |
|
|
| Not yet recruiting | 3 | 150 | | Intravitreal injection of KSI-301 (5mg) ;Aflibercept 2 mg intravitreal injection | Kodiak Sciences China Inc; Beijing Tongren Hospital Affiliated to Capital Medical University, self-funded | Diabetic Macular Edema | | | | |
ChiCTR2100053499: A Prospective, Randomized, Double-Masked, Active Comparator-Controlled, Multi-Center, Two-Arm, Phase III Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Visual Impairment Due to Treatment-Naive Macular Edema Secondary to Retinal Vein Occlusion (RVO) |
|
|
| Suspended | 3 | 170 | | Intravitreal injection of KSI-301 (5mg) ;Intravitreal injection of aflibercept 2mg | Kodiak Sciences China Inc.; Beijing Tongren Hospital Affiliated to Capital Medical University, self-funded | Macular Edema Secondary to Retinal Vein occlusion | | | | |
BEACON, NCT04592419 / 2020-001061-37: A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO) |
|
|
| Completed | 3 | 568 | Europe, US, RoW | KSI-301, Aflibercept, Eylea, Sham Procedure | Kodiak Sciences Inc | Macular Edema, Retinal Vein Occlusion | 06/22 | 01/23 | | |
| Completed | 3 | 434 | Europe, Japan, RoW | FYB203 (Proposed aflibercept biosimilar), Eylea® (Aflibercept) | Bioeq GmbH | Neovascular Age-related Macular Degeneration | 06/22 | 05/23 | | |
| Completed | 3 | 553 | Europe, Japan, US, RoW | Faricimab, VABYSMO®, faricimab-svoa, RO6867461, RG7716, Aflibercept, Eylea, Sham Procedure | Hoffmann-La Roche, Chugai Pharmaceutical | Macular Edema, Branch Retinal Vein Occlusion | 07/22 | 06/23 | | |
Mylight, NCT04864834 / 2019-004838-41: Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With Neovascular Age-related Macular Degeneration |
|
|
| Completed | 3 | 485 | Europe, Japan, US, RoW | SOK583A1 (40 mg/mL), Eylea EU (40 mg/mL) | Sandoz | Neovascular Age-related Macular Degeneration | 07/22 | 05/23 | | |
PULSAR, NCT04423718 / 2019-003851-12: Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye |
|
|
| Active, not recruiting | 3 | 1011 | Europe, Canada, Japan, US, RoW | Aflibercept High Dose VEGF Trap-Eye (BAY86-5321), Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321) | Bayer, Regeneron Pharmaceuticals | Neovascular Age-Related Macular Degeneration | 07/22 | 08/24 | | |
COMINO, NCT04740931 / 2020-000441-13: A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion |
|
|
| Completed | 3 | 729 | Europe, Japan, US, RoW | Faricimab, VABYSMO®, faricimab-svoa, RG7716, RO6867461, Aflibercept, Eylea, Sham Procedure | Hoffmann-La Roche, Chugai Pharmaceutical | Macular Edema, Central Retinal Vein Occlusion, Hemiretinal Vein Occlusion | 08/22 | 07/23 | | |
2019-004132-37: A clinical study to determine if a potential new drug (SCD411) is similar to the marketed product Eylea® in the efficacy, is safe and similar tolerable and distributed, by testing its effect on the body in patients with Neovascular Age-related Macular Degeneration |
|
|
| Not yet recruiting | 3 | 576 | Europe, RoW | SCD411, Eylea, SCD411, Solution for injection, Eylea | SamChunDang Pharm. Co. Ltd., Sam Chun Dang Pharm. Co. Ltd, SamChunDang Pharm. Co. Ltd. | Neovascular Age-related Macular Degeneration, Age-related macular degeneration (AMD) is a disease that impacts the central area of the retina in the eye, called the macula. AMD is a leading cause of blindness, Diseases [C] - Eye Diseases [C11] | | | | |
NCT04480463: A Study to Comparing SCD411 and Eylea® in Subjects With Wet Age-related Macular Degeneration (AMD) |
|
|
| Completed | 3 | 576 | Europe, Japan, US, RoW | SCD411, Aflibercept, Eylea® | Sam Chun Dang Pharm. Co. Ltd. | Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration | 09/22 | 09/22 | | |
NCT04739306: Study to Compare Efficacy and Safety of CT-P42 in Comparison With Eylea in Patients With Diabetic Macular Edema |
|
|
| Completed | 3 | 348 | Europe | CT-P42, Eylea | Celltrion | Diabetic Macular Edema (DME) | 10/22 | 04/23 | | |
NCT04113538: Treat and Extend Analysis Trial With Aflibercept in Wet-AMD |
|
|
| Active, not recruiting | 3 | 40 | Canada | Aflibercept, Eylea | Michel Giunta, Bayer | Wet Age-related Macular Degeneration | 01/23 | 05/23 | | |
KINGLET, NCT04058067: To Compare Brolucizumab to Aflibercept in Chinese Patients With Visual Impairment Due to Diabetic Macular Edema |
|
|
| Completed | 3 | 263 | RoW | Brolucizumab, RTH258, Aflibercept, Eylea | Novartis Pharmaceuticals | Diabetic Macular Edema | 01/23 | 01/23 | | |
NCT05704725: A Study to Evaluate ABP 938 and Aflibercept (Eylea®) in Participants With Chorioretinal Vascular Disease (CVD) |
|
|
| Completed | 3 | 49 | US | ABP 938, Aflibercept, Eylea® | Amgen | Chorioretinal Vascular Disease | 02/23 | 03/23 | | |
DAYLIGHT, NCT04964089 / 2021-000225-27: A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) |
|
|
| Completed | 3 | 557 | US | KSI-301, Aflibercept, Eylea, Sham Procedure | Kodiak Sciences Inc | Wet Age-related Macular Degeneration | 03/23 | 04/23 | | |
2020-004278-23: A Phase 3 study to evaluate the efficacy and safety of CT-P42 versus Eylea as treatment for patients with Diabetic Macular Edema. |
|
|
| Not yet recruiting | 3 | 360 | Europe | Aflibercept, Eylea, CT-P42, Solution for injection, Eylea 40 mg/mL solution for injection in a vial | CELLTRION Inc., CELLTRION Inc. | Diabetic Macular Edema, Diabetic Macular Edema, Diseases [C] - Eye Diseases [C11] | | | | |
| Terminated | 3 | 459 | Europe, US, RoW | KSI-301, Aflibercept, Eylea, Sham Procedure | Kodiak Sciences Inc | Diabetic Macular Edema | 04/23 | 08/23 | | |
| Terminated | 3 | 460 | Europe, US | KSI-301, Aflibercept, Eylea, Sham Procedure | Kodiak Sciences Inc | Diabetic Macular Edema | 05/23 | 08/23 | | |
NCT04572698: A Study to Compare LY09004 and Eylea in the Treatment of Wet Age-related Macular Degeneration（wAMD） |
|
|
| Not yet recruiting | 3 | 416 | NA | LY09004, Recombinant Human Vascular Endothelial Growth Factor Receptor Antibody Fusion Protein Eye Injection, Eylea | Luye Pharma Group Ltd., Shan Dong Boan Biotechnology Co., Ltd(Co-sponsor) | Age Related Macular Degeneration | 06/23 | 12/23 | | |
NCT05324774: Efficacy and Safety of 9MW0813 in Subjects With Diabetic Macular Edema |
|
|
| Recruiting | 3 | 346 | RoW | 9MW0813, Aflibercept, Eylea® | Mabwell (Shanghai) Bioscience Co., Ltd. | Diabetic Macular Edema | 09/23 | 07/24 | | |
| Active, not recruiting | 3 | 990 | Europe, Canada, US, RoW | 2.0 mg OPT-302, 2.0 aflibercept, Sham | Opthea Limited | Neovascular Age-related Macular Degeneration | 07/25 | 07/26 | | |
| Active, not recruiting | 3 | 413 | Europe, Japan, RoW | AVT06 (proposed aflibercept biosimilar), Eylea® (Aflibercept) | Alvotech Swiss AG | Neovascular (Wet) AMD | 11/23 | 10/24 | | |
NCT06223958: Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration |
|
|
| Recruiting | 3 | 300 | US | OTX-TKI (axitinib implant), Aflibercept | Ocular Therapeutix, Inc., Fortrea, Duke University | Neovascular Age-Related Macular Degeneration | 04/26 | 09/27 | | |
NCT04047472: Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Chinese Patients With Neovascular Age-Related Macular Degeneration |
|
|
| Completed | 3 | 397 | RoW | Brolucizumab 6mg, Aflibercept 2 mg | Novartis Pharmaceuticals | Neovascular Age-Related Macular Degeneration | 02/24 | 02/24 | | |
NCT05989126: Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS) |
|
|
| Completed | 3 | 35 | US | aflibercept 8 mg PFS, EYLEA ® HD, BAY86-5321 | Regeneron Pharmaceuticals | Diabetic Macular Edema (DME), Neovascular Age-Related Macular Degeneration (nAMD) | 05/24 | 05/24 | | |
PHOTONiC, NCT06422507: A Study to Learn More About How Well 8 Milligram Aflibercept Works and How Safe it is in Chinese Participants With Diabetic Macular Edema |
|
|
| Recruiting | 3 | 322 | RoW | 8 mg aflibercept (BAY 86-5321) (High Dose), 2 mg aflibercept (EYLEA, BAY 86-5321), Sham | Bayer, Regeneron Pharmaceuticals | Diabetic Macular Edema | 05/26 | 05/26 | | |
NCT06470373: A Phase 3 Clinical Trial to Compare RBS-001 to Eylea® in Subjects With Neovascular Age-Related Macular Degeneration |
|
|
| Not yet recruiting | 3 | 434 | US | RBS-001 Solution for intravitreal injection, Eylea® Solution for intravitreal injection | Rophibio, Inc. | Neovascular Age-related Macular Degeneration (nAMD) | 09/26 | 09/26 | | |
QUASAR, NCT05850520: A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion) |
|
|
| Recruiting | 3 | 822 | Europe, Japan, US, RoW | Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose, Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg, Sham, Fluorescein | Bayer, Regeneron Pharmaceuticals | Macular Edema Secondary to Retinal Vein Occlusion | 11/24 | 05/25 | | |
TELeMAC, NCT03845049: Comparative Multicenter Randomized Study of Aflibercept Versus Placebo in Macular Telangiectasia Type 1 |
|
|
| Recruiting | 3 | 46 | Europe | Inclusion examinations, Aflibercept Injection [Eylea], SHAM injection, Examinations during study (every month) | Centre Hospitalier Universitaire Dijon | Macular Telangiectasia | 01/25 | 01/25 | | |
TIGER, NCT04663750: Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (). |
|
|
| Recruiting | 3 | 210 | Europe | Pars plana vitrectomy, Intravitreal 2 mg aflibercept (Eylea, Bayer) will be injected at baseline then monthly for two further doses, then 2-monthly until month 12, Aflibercept (Eylea, Bayer), subretinal injection of recombinant TPA (Alteplase) up to a maximum of 25 micrograms in 0.2 mls, Actilyse (Boehringer Ingelheim), Intravitreal 20% sulfahexafluoride (SF6) gas tamponade | King's College Hospital NHS Trust, King's College London, Fight for Sight (Funder) | Eye Diseases, Macular Degeneration, Wet, Sub-Macular Hemorrhage | 01/25 | 12/25 | | |
| Recruiting | 3 | 465 | Canada, US | RGX-314 Dose 1, RGX-314 Dose 2, Aflibercept (EYLEA®) | AbbVie | AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, WetAMD, CNV | 02/25 | 12/25 | | |
| Active, not recruiting | 3 | 96 | Europe, Japan, RoW | Eylea (Aflibercept, BAY86-5321), Laser photocoagulation | Bayer, Regeneron Pharmaceuticals | Retinopathy of Prematurity (ROP) | 10/25 | 10/25 | | |
NCT05727397: Efficacy and Safety of RC28-E Versus Aflibercept |
|
|
| Recruiting | 3 | 432 | RoW | RC28-E, Aflibercept, Eylea | RemeGen Co., Ltd. | Wet Age-related Macular Degeneration | 11/25 | 12/25 | | |
ChiCTR2300069823: Therapeutics and Pharmacogenetics of Brolucizumab and Other Anti-VEGF Agents in Treating Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy – Deep Learning towards Precision Medicine |
|
|
| Not yet recruiting | 3 | 864 | | 3 Beovu loading doses, BCVA and SDOCT exam every 4-6 week starting from week 12, further injection as clinically needed ;3 Eylea loading doses, BCVA and SDOCT exam every 4-6 week starting from week 12, further injection as clinically needed ;3 Lucentis loading doses, BCVA and SDOCT exam every 4-6 week starting from week 12, further injection as clinically needed ;3 Beovu loading doses, BCVA and SDOCT exam every 4-6 week starting from week 12, further injection as clinically needed ;3 Eylea loading doses, BCVA and SDOCT exam every 4-6 week starting from week 12, further injection as clinically needed ;3 Lucentis loading doses, BCVA and SDOCT exam every 4-6 week starting from week 12, further injection as clinically needed ;3 loading doses of Eylea or Lucentis as clinically indicated every 1 month; BCVA and SDOCT exam 4-6 weeks after the third injection ;3 loading doses of Eylea or Lucentis as clinically indicated every 1 month; BCVA and SDOCT exam 4-6 weeks after the third injection | Research Office, Health Bureau; Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Health and Medical Research Fund | Neovascular age-related macular degeneration, polypoidal choroidal vasculopathy | | | | |
NCT05885503: Efficacy and Safety of RC28-E Versus Aflibercept in Diabetic Macular Edema |
|
|
| Recruiting | 3 | 316 | RoW | RC-28E, Aflibercept | RemeGen Co., Ltd. | Diabetic Macular Edema | 06/26 | 06/26 | | |
| Not yet recruiting | 3 | 159 | NA | Episcleral Brachytherapy, Aflibercept Injection | Salutaris Medical Devices, Inc. | Age-Related Macular Degeneration, Polypoid Choroidal Vasculopathy | 09/26 | 09/28 | | |
NCT05972473: A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With nAMD |
|
|
| Recruiting | 3 | 600 | RoW | Aflibercept Ophthalmic, IBI302 | Innovent Biologics (Suzhou) Co. Ltd. | Neovascular Age-related Macular Degeneration | 02/27 | 04/27 | | |
2013-003272-12: Clinical Efficacy and Mechanistic Evaluation of Aflibercept for Proliferative Diabetic Retinopathy |
|
|
| Ongoing | 2/3 | 220 | Europe | Aflibercept, EMA/CHMP/299413/2012, Eylea, Eylea | Moorfields Eye Hospital, NIHR MRC - EME grant, Bayer PLC | Proliferative Diabetic Retinopathy (PDR) | | | | |
| Active, not recruiting | 2/3 | 660 | Europe, Canada, Japan, US, RoW | aflibercept, EYLEA®, BAY86-5321, High-dose aflibercept | Regeneron Pharmaceuticals, Bayer | Diabetic Macular Edema, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus | 05/22 | 06/24 | | |
ODYSSEY, NCT05891548: Study to Evaluate Suprachoroidally Administered CLS-AX in the Treatment of Neovascular Age-Related Macular Degeneration |
|
|
| Active, not recruiting | 2b | 60 | US | CLS-AX, axitinib injectable suspension, Aflibercept, Eylea | Clearside Biomedical, Inc. | Neovascular Age-related Macular Degeneration | 07/24 | 07/24 | | |
2013-004203-39: Study of efect of intravitreal aflibercept in subjects with prolipherative diabetic retinopathy |
|
|
| Ongoing | 2 | 50 | Europe | Solution for injection, Eylea | Fakultní nemocnice Královské Vinohrady, Fakultní nemocnice Královské Vinohrady | prolipherative diabetic retinopathy, advanced retinal changes by patients wits diabetes, Diseases [C] - Eye Diseases [C11] | | | | |
2013-005549-35: To establish the safety and tolerability of intravitreous administration of altering regimens of Fovista? (Anti-PDGF-B pegylated aptamer) administered in combination with Anti-VEGF therapy (Lucentis®, Avastin® or Eylea®) in subjects with subfoveal neovascular age-related macular degeneration. Evaluar la seguridad y la tolerabilidad de la administración intravítrea de diferentes pautas de Fovista? (aptámero pegilado anti-PDGF-B) y el tratamiento anti-VEGF (Lucentis®, Avastin® o Eylea®) en pacientes con degeneración macular neovascular asociada a la edad. |
|
|
| Ongoing | 2 | 25 | Europe | Fovista, Lucentis, Eylea, Avastin, E10030, Solution for injection, Lucentis 10 mg/mL, Eylea, Avastin | Barcelona Macula Foundation Research for Vision, Barcelona Macula Foundation | Neovascular age-related macular degeneration Degeneración macular neovascular asociada a la edad., Neovascular age-related macular degeneration Degeneración macular neovascular asociada a la edad., Diseases [C] - Eye Diseases [C11] | | | | |
2013-001856-36: Efficacy and safety of Aflibercept (Eylea®) in proliferative diabetic retinopathy |
|
|
| Ongoing | 2 | 40 | Europe | aflibercept, Eylea® 40mg/ml, Eylea® 40mg/ml | CHU DE POITIERS, CHU DE POITIERS, BAYER | Percentage of patients showing regression of retinal neovascularization between baseline and month 12 in the Aflibercept group versus laser group | | | | |
| Not yet recruiting | 2 | 500 | US | Drug: REGN2176-3 and 2mg. alflibercept (Eylea®), alflibercept is also known as Eylea | North Shore Long Island Jewish Health System | Macula Degeneration | 11/17 | 01/18 | | |
| Ongoing | 2 | 40 | Europe | Aflibercept, Solution for injection, Eylea | York Teaching Hospital, Bayer Healthcare UK | Neovascular Age-related macular degeneration, wet AMD, Diseases [C] - Eye Diseases [C11] | | | | |
2019-001506-17: A study to evaluate THR-149 treatment for diabetic macular oedema |
|
|
| Not yet recruiting | 2 | 126 | Europe, RoW | THR-149, Aflibercept, THR-149, Solution for injection, Eylea 40 mg/ml solution for injection | Oxurion NV, OXURION NV, Oxurion NV | Diabetic Macular Oedema (DME), Diabetic macular oedema is a swelling in the light-sensitive tissue in the back of the eye (called the retina) in people with diabetes, caused by leaking of blood vessels., Diseases [C] - Eye Diseases [C11] | | | | |
2018-003298-90: A clinical study of OPT-302 with aflibercept compared to aflibercept plus sham in patients with diabetic macular edema |
|
|
| Not yet recruiting | 2 | 108 | Europe | OPT-302, Solution for injection | Opthea Ltd, Opthea Ltd | Persistent central-involved diabetic macular edema, Diabetic macular edema is characterized by accumulation of fluid and retinal thickening within the macula and is responsible for most of the central visual loss experienced in the diabetic population, Diseases [C] - Eye Diseases [C11] | | | | |
2019-000642-35: Multicentre study to evaluate safety and efficacy of HL217 topical ophthalmologic solution in the treatment of exudative Age-Related Macular Degeneration Многоцентрово изпитване за оценка на безопасността и ефикасността на HL217 офталмологичен разтвор за локално приложение в лечението на ексудативна дегенерация на макулата, свързана с възрастта |
|
|
| Not yet recruiting | 2 | 90 | Europe, RoW | HL217, aflibercept, Eye drops, Solution for injection in pre-filled syringe, EYLEA | HANLIM PHARM CO., LTD, HANLIM PHARM CO., LTD | AMD (age-related macular degeneration), age-related macular degeneration, Diseases [C] - Eye Diseases [C11] | | | | |
2021-001213-36: Treatment of diabetic macular edema and wet age-related macular degeneration in the eye with a substance suppressing a growth factor (TGF-Beta2) |
|
|
| Not yet recruiting | 2 | 60 | Europe | TGF-ß2 Antisense, Eylea, ISTH0036, Powder for solution for injection, Solution for injection in pre-filled syringe, Eylea | Isarna Therapeutics GmbH, Isarna Therapeutics GmbH | Neovascular age-related macular degeneration (nAMD)Diabetic Macular edema (DME), age-related disease of the macula due to the formation of abnormal blood vessels in the eyeMacular edema caused by diabetes, Diseases [C] - Eye Diseases [C11] | | | | |